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Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
To the Editor: Since August 2014, the Botswana Harvard AIDS Institute Partnership has conducted birth outcome surveillance at eight government hospitals throughout Botswana. A primary ongoing aim of the surveillance is to evaluate the prevalence of neural-tube defects associated with exposure to antiretroviral drugs from the time of conception (the risk period for neural-tube defects ends approximately 28 days after conception). At each site, trained government midwives perform surface examinations of consecutive live-born and stillborn infants who are born in the hospital to women infected with human immunodeficiency virus (HIV) and to women without HIV infection. As part of an institutional review board-approved research protocol, research assistants photograph major abnormalities after obtaining written informed consent from the mother; a medical geneticist reviews photos quarterly, without knowledge of mothers' HIV infection status or exposure to antiretroviral drugs. In May 2016, Botswana changed its first-line antiretroviral therapy from tenofovir-emtricitabine-efavirenz to tenofoviremtricitabine-dolutegravir for all adults, a change that allowed for the inclusion of dolutegravir in surveillance.
We recently reported that the risk of adverse birth outcomes or congenital abnormalities among women who started dolutegravir-based antiretroviral therapy after conception (including therapy initiated during the first trimester of pregnancy) was not higher than the risk among women who started efavirenz-based therapy after conception. 1 However, in April 2018, we detected a higher-thanexpected number of neural-tube defects among infants born to women who started treatment with dolutegravir before conception. We performed an unplanned interim analysis to compare the prevalence of neural-tube defects among infants born to women who had been receiving dolutegravirbased antiretroviral therapy from the time of conception with the prevalence in other exposure groups. For each exposure group, we calculated the prevalence of neural-tube defects (and 95% confidence interval, calculated with the Wilson method) and the difference in prevalence relative to the group with dolutegravir-based therapy from the time of conception (and 95% confidence interval, calculated with the Newcombe method). 2 As of May 1, 2018, a total of 89,064 births had been included in our surveillance; 88,755 births (99.7%) had an infant surface examination that could be evaluated, with 86 neural-tube defects identified (0.10% of births; 95% confidence interval [CI], 0.08 to 0.12) (57% identified with a photograph, 43% identified by description myelomeningocele, 30 of anencephaly, 13 of encephalocele, and 1 of iniencephaly. Among the 426 infants born to HIV-positive women who had been taking dolutegravir-based antiretroviral therapy from the time of conception, 4 (0.94%) had a neural-tube defect. The defects in these 4 infants were encephalocele, myelomeningocele (along with undescended testes), and iniencephaly (along with major limb defect), all three of which were identified with photos, and anencephaly, which was identified by description. The 4 mothers delivered in three geographically separated hospitals over a 6-month period; none had epilepsy or diabetes or received folate supplementation at conception. In comparison, neural-tube defects occurred in 14 (0.12%) of 11,300 infants born to women who had been exposed to any non-dolutegravir antiretrovi-ral therapy from the time of conception, 0 (0.00%) of 2812 infants born to women who had been exposed to dolutegravir treatment that was started in pregnancy, and 61 (0.09%) of 66,057 infants born to HIV-uninfected women (Fig. 1) . Seven neural-tube defects occurred in other exposure groups. In the analysis of the prevalence of neuraltube defects associated with exposure to antiretroviral therapy from the time of conception, the difference between non-dolutegravir-based antiretroviral therapy (prevalence, 0.12%) and dolutegravir-based antiretroviral therapy (0.94%) was −0.82 percentage points (95% CI, −0.24 to −2.3).
In conclusion, we found a potential early signal for an increased prevalence of neural-tube defects in association with dolutegravir-based antiretroviral therapy from the time of conception. Our study There were 7 additional infants with neural-tube defects in the full cohort: 3 born to women who started nondolutegravir (DTG) antiretroviral therapy (ART) during pregnancy, 3 to human immunodeficiency virus (HIV)infected women who did not receive ART during pregnancy, and 1 to a woman of unknown HIV infection status who did not receive ART. Among the women who had been receiving any non-DTG ART at conception, 5675 were receiving tenofovir-emtricitabine-efavirenz, 1446 tenofovir-emtricitabine-nevirapine, 2439 zidovudine-lamivudine-nevirapine, 452 tenofovir-emtricitabine-lopinavir-ritonavir, 312 zidovudine-lamivudine-lopinavir-ritonavir, 242 other specified ART regimens, and 734 unspecified non-DTG regimens. Among the women receiving DTG treatment that was started during pregnancy, the median gestational age at the initiation of ART was 19 weeks (interquartile range, 14 to 25), and there were 75 women who started ART at a gestational age of less than 6 weeks. is ongoing, and more data are needed to confirm or refute this signal, given the small number of events and the small difference in prevalence. Rebecca Zash, M.D.
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1-Mutated AML
To the Editor: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of hematologic neoplasms. CHIP is most common in older patients, who usually carry a single somatic mutation (which provides a fitness advantage) in a minority of hematopoietic cells. 1,2 Here, we describe the striking sequential onset within 2 years of angioimmunoblastic T-cell lymphoma (AITL) with mutation in the gene encoding ras homolog family member A (RHOA) 3 and acute myeloid leukemia (AML) with mutation in the gene encoding nucleophosmin 1 (NPM1) 4 in a 45-year-old man with CHIP. The relatively young age of the patient was unusual, because both of these cancers are typically diagnosed in elderly patients. We also describe the common origin of these two neoplasms from high-risk CHIP driven by multiple TET2 and ASXL1 mutations in virtually all bone marrow cells. (Additional details are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.) After the patient presented with AITL ( Fig.  1A) , molecular studies in formalin-fixed lymph node DNA identified a clonal RHOA G17V mutation, which is characteristic of AITL, 3 along with four inactivating TET2 and ASXL1 somatic mutations that are typical of CHIP. 2 These four mutations were also documented in the staging aspirate of bone marrow and in purified CD34+ hemato-poietic cells at frequencies of 7.9 to 49.3%, which were much higher than the frequencies of the RHOA G17V mutation (0.04 to 0.24%), which was consistent with minimal bone marrow involvement by AITL.
The patient had a complete remission after six cycles of chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone (CHOEP), followed by autologous hematopoietic stem-cell transplantation. Approximately 1 year after the diagnosis of AITL, the patient received the diagnosis of AML involving the bone marrow and skin, which were infiltrated by leukemic cells that were negative for CD34 and aberrantly positive for cytoplasmic NPM1 5 (Fig. 1B) . In both the bone marrow aspirate and skin-biopsy sample, we identified a clonal NPM1 mutation type A 4 and two subclonal KRAS mutations, along with the same four preleukemic TET2 and ASXL1 mutations, but the RHOA G17V mutation was either absent or only minimally present. The patient subsequently died of AML despite receiving intensive chemotherapy. (Details regarding this treatment are provided in the Supplementary Appendix.)
Variant allele frequencies in preleukemic bone marrow suggested the first occurrence in a hematopoietic stem cell of the TET2 Q1654* mutation, resulting in a clone that eventually replaced the entire bone marrow while acquiring additional subclonal mutations (Fig. 2) . In particular, a sec- 
